Results for tag: "Familial Amyloid Polyneuropathy Drug"

Familial Amyloid Polyneuropathy (FAP) is a rare, inherited, progressive neurological disorder caused by the accumulation of abnormal proteins in the peripheral nerves. It is characterized by progressive sensory and motor nerve damage, leading to numbness, tingling, and weakness in the extremities. Treatment of FAP is focused on slowing the progression of the disease and managing symptoms. Drugs used to treat FAP are typically classified as central nervous system (CNS) drugs. These drugs are designed to reduce the accumulation of abnormal proteins in the peripheral nerves, as well as to reduce inflammation and pain. Common CNS drugs used to treat FAP include tafamidis, diflunisal, and doxycycline. Companies in the FAP drug market include Pfizer, Merck, and Novartis. Other companies involved in the development of FAP drugs include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Prothena Biosciences. Show Less Read more